New York, May 24, 2026, 15:03 (EDT)
Ribbon Acquisition Corp.’s Class A shares on Nasdaq closed flat heading into the long U.S. weekend, as traders looked ahead to see how much cash and backing the SPAC will keep for its planned merger with Japan’s DRC Medicine. Ribbon is set up as a special purpose acquisition company, or SPAC, meant to merge with a private firm and take it public.
There won’t be any regular U.S. stock trading Monday, with Nasdaq showing Memorial Day—May 25, 2026—as a market holiday. That means the next time investors can trade Ribbon’s securities is Tuesday.
Ribbon Class A shares (RIBB) ended at $10.68, off a penny from where they closed before. Only 25 shares changed hands, leaving the market cap near $56.5 million. Trading was so light that small moves on the tape didn’t signal much about bigger demand or selling in the stock.
Stocks climbed Friday with the broader market showing strength. The Dow Jones Industrial Average ended at another record and the S&P 500 stretched its run to an eighth week of gains. “Earnings season looked really good,” said James St. Aubin, chief investment officer at Ocean Park Asset Management, in comments to Reuters. Reuters
Ribbon isn’t acting like an operating biotech right now. The most recent 10-Q says operations haven’t started and management doesn’t expect revenue until after a business combination. As of March 31, the company had $37.7 million in cash and marketable securities in trust, with 3.56 million Class A shares subject to possible redemption. The trust account is the SPAC cash pool for public shareholders.
Ribbon is set to merge with DRC Medicine, a healthcare and biotech firm from Tokyo. DRC said in June 2025 that the deal gives the joint company an initial pro forma equity value near $422.15 million, if there aren’t any redemptions. DRC could also see around $50.42 million in cash proceeds on those terms.
DRC’s leadership put the deal in the context of its medical-device and diagnostic strategy. “The deal will give us the resources to go after key trends in the industry,” Dr. Marumi Okazaki, DRC president and CEO, said. Ribbon Chairman and CEO Angshuman Ghosh said in a statement it’s a “great opportunity” for Ribbon to step into healthcare and biotech.
Structure remains a key factor. In a filing from June 2025, DRC Medicine’s shareholders were set to swap their shares for new shares in a public holding company. Ribbon would shift its place of incorporation from the Cayman Islands to Delaware, then merge into a public company subsidiary.
But there’s a risk shareholders just take the cash and leave. Ribbon said holders of 1,436,867 public Class A shares redeemed at a January meeting, getting about $14.94 million total, or around $10.40 per share. Redemption is when a SPAC investor opts for cash from the trust, not shares after a merger. More redemptions, delays, or less deal backing could shrink the cash left for DRC or make closing harder.
Competitive context is tight right now. Before the merger goes through, Ribbon lines up against other small blank-check firms trading near trust value—not revenue-generating healthcare stocks. So filings, redemptions, and vote timing are bigger factors than sector comps.
The focus next week is paperwork, not price. Traders are looking for any new filing, proxy statement or update on extensions. Ribbon’s 10-Q said a meeting for the planned trust-agreement change got pushed back several times, now set for September 14, 2026, after an extension deposit in April.
Ribbon’s stock stays muted for now. With the market closed Monday and broader shares holding up, the stock is near the typical SPAC cash value ahead of a merger vote. What would move it isn’t another low-volume session, but a solid update on the DRC Medicine merger—either for or against.
